All In Biotech

Free tool

FAERS Monitor: Xeljanz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203214 or its brand name (Xeljanz, Tofacitinib Citrate). Reports on generic versions are filed under their own applications.

Reports

107,010

Serious

65,558

61% of reports

Hospitalization

19,573

Death reported

8,054

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective31,730
  • pain17,197
  • rheumatoid arthritis17,065
  • arthralgia14,265
  • off label use13,206
  • condition aggravated13,157
  • fatigue13,129
  • joint swelling12,494
  • drug intolerance11,519
  • rash10,773
  • headache9,470
  • abdominal discomfort9,187
  • synovitis9,149
  • arthropathy8,624
  • alopecia8,446

Reports by year received

View as table
YearReports
20081
20091
20111
201228
20131,742
20142,728
20154,589
20167,933
20178,366
201810,282
201912,768
202015,351
202110,605
202212,353
20237,021
20246,600
20254,953
20261,688

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,947,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
synovitisSignal9,149201.2195.5899,430
arthropathySignal8,62435.935.1247,886
rheumatoid arthritisSignal17,06534.634.1475,559
drug intoleranceSignal11,51926.526.0249,813
joint swellingSignal12,49422.622.2232,290
abdominal discomfortSignal9,18711.311.182,435
condition aggravatedSignal13,1578.88.788,864
alopeciaSignal8,4468.88.656,305
arthralgiaSignal14,2656.96.871,545
painSignal17,1975.65.665,594
rashSignal10,7735.04.933,870
drug ineffectiveSignal31,7304.84.8100,144
fatigueSignal13,1293.43.322,145
headacheSignal9,4703.02.912,808
off label useSignal13,2063.02.918,026

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.